Botox Injection, Powder, Lyophilized, For Solution
NDC Package 0023-3921-03

11-digit billing NDC: 00023392103

Package Information

Botox (onabotulinumtoxina) injection is bOTOX is contraindicated: In patients who are hypersensitive to any botulinum toxin product or to any of the components in the formulation [see Warnings and Precautions (5.4)]. In the presence of infection at the proposed injection site(s). This formulation utilizes a injection, powder, lyophilized, for solution delivery system. Marketed by Allergan, Inc., this product is identified by NDC 0023-3921 and is authorized under FDA application BLA103000.

Identification & Billing

NDC Package Code
0023-3921-03
Package Description
1 VIAL in 1 CARTON / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL
Product Code
11-Digit Billing Format
00023392103
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Botox
Non-Proprietary Name
Onabotulinumtoxina
Substance Name
Botulinum Toxin Type A
Dosage Form
Injection, Powder, Lyophilized, For Solution - A dosage form intended for the solution prepared by lyophilization ("freeze drying"), a process which involves the removal of water from products in the frozen state at extremely low pressures; this is intended for subsequent addition of liquid to create a solution that conforms in all respects to the requirements for Injections.
Administration Route
  • Intradermal - Administration within the dermis.
  • Intramuscular - Administration within a muscle.
Usage Information
BOTOX is contraindicated: In patients who are hypersensitive to any botulinum toxin product or to any of the components in the formulation [see Warnings and Precautions (5.4)]. In the presence of infection at the proposed injection site(s). For intradetrusor injection in patients with a urinary tract infection; or in patients with urinary retention or post-void residual (PVR) urine volume >200 mL who are not routinely performing clean intermittent self-catheterization (CIC) [see Warnings and Precautions (5.12, 5.13)].

Regulatory & Marketing

Labeler Name
Allergan, Inc.
Product Type
Human Prescription Drug
FDA Application #
BLA103000
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
01-11-2010
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
Yes

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (0023-3921). Click a package code to view its specific billing and regulatory data.

1 VIAL in 1 CARTON / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0023-3921-03 identifies a specific commercial package of 1 vial in 1 carton / 1 injection, powder, lyophilized, for solution in 1 vial of Botox, a human prescription drug labeled by Allergan, Inc.. This injection, powder, lyophilized, for solution is formulated for intradermal; intramuscular use and contains botulinum toxin type a as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Allergan, Inc. on January 11, 2010. The current certification is valid through December 31, 2027.

How is this Allergan, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00023392103. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0023-3921-03
11-Digit CMS (5-4-2)
00023-3921-03

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.